AU2022265718A1 - Deubiquitinase-targeting chimeras and related methods - Google Patents
Deubiquitinase-targeting chimeras and related methods Download PDFInfo
- Publication number
- AU2022265718A1 AU2022265718A1 AU2022265718A AU2022265718A AU2022265718A1 AU 2022265718 A1 AU2022265718 A1 AU 2022265718A1 AU 2022265718 A AU2022265718 A AU 2022265718A AU 2022265718 A AU2022265718 A AU 2022265718A AU 2022265718 A1 AU2022265718 A1 AU 2022265718A1
- Authority
- AU
- Australia
- Prior art keywords
- tautomer
- stereoisomer
- solvate
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181796P | 2021-04-29 | 2021-04-29 | |
| US63/181,796 | 2021-04-29 | ||
| US202163186739P | 2021-05-10 | 2021-05-10 | |
| US63/186,739 | 2021-05-10 | ||
| US202163273118P | 2021-10-28 | 2021-10-28 | |
| US63/273,118 | 2021-10-28 | ||
| US202263311781P | 2022-02-18 | 2022-02-18 | |
| US63/311,781 | 2022-02-18 | ||
| PCT/US2022/027120 WO2022232634A1 (en) | 2021-04-29 | 2022-04-29 | Deubiquitinase-targeting chimeras and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022265718A1 true AU2022265718A1 (en) | 2023-11-02 |
Family
ID=81748638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022265718A Pending AU2022265718A1 (en) | 2021-04-29 | 2022-04-29 | Deubiquitinase-targeting chimeras and related methods |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240252655A1 (enExample) |
| EP (1) | EP4329815A1 (enExample) |
| JP (1) | JP2024515828A (enExample) |
| KR (1) | KR20240004584A (enExample) |
| CN (1) | CN120225225A (enExample) |
| AU (1) | AU2022265718A1 (enExample) |
| BR (1) | BR112023022315A2 (enExample) |
| CA (1) | CA3216614A1 (enExample) |
| IL (1) | IL307863A (enExample) |
| MX (1) | MX2023012852A (enExample) |
| WO (1) | WO2022232634A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024220874A2 (en) * | 2023-04-21 | 2024-10-24 | Icahn School Of Medicine At Mount Sinai | Otub1 small-molecule binders and otub1-recruiting deubiquitinase-targeting chimeras (dubtacs) |
| WO2024233280A1 (en) * | 2023-05-05 | 2024-11-14 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional small molecules that deubiquitinylate and stabilize target proteins by recruiting usp7 |
| WO2024264072A2 (en) * | 2023-06-23 | 2024-12-26 | Stablix, Inc. | Parp inhibitors |
| CN119350422B (zh) * | 2024-12-25 | 2025-04-04 | 中国药科大学 | 一种去泛素化酶靶向嵌合体化合物及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008109031A (ru) | 2005-08-11 | 2009-09-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы муковисцидозного трансмембранного регулятора проводимости |
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| PE20080695A1 (es) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| PL2168966T3 (pl) | 2007-06-15 | 2017-06-30 | Msd K.K. | Pochodna bicykloaniliny |
| CN102743385B (zh) * | 2007-11-16 | 2014-09-17 | 沃泰克斯药物股份有限公司 | Atp结合盒转运蛋白的异喹啉调节剂 |
| US20110035601A1 (en) | 2007-12-21 | 2011-02-10 | University Of Virginia Patent Foundation | System, method and computer program product for protecting software via continuous anti-tampering and obfuscation transforms |
| EP2303885B1 (en) | 2008-06-12 | 2013-07-03 | Merck Sharp & Dohme Corp. | Process for producing bicycloaniline derivatives |
| CZ2009620A3 (cs) | 2009-09-22 | 2011-04-06 | Ústav makromolekulární chemie AV CR, v.v.i. | Surovina pro výrobu polyurethanu a zpusob její výroby z odpadního polyurethanu |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| WO2011133953A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| KR20150097660A (ko) | 2012-12-19 | 2015-08-26 | 노파르티스 아게 | Cftr 채널을 억제하기 위한 트리시클릭 화합물 |
| CA2895656A1 (en) | 2012-12-19 | 2014-06-26 | Novartis Ag | Tricyclic compounds as cftr inhibitors |
| WO2018037350A1 (en) | 2016-08-23 | 2018-03-01 | Laurus Labs Limited | Solid forms of lumacaftor, process for its preparation and pharmaceutical compositions thereof |
| CA3103205A1 (en) * | 2018-06-13 | 2019-12-19 | Amphista Therapeutics Ltd | Bifunctional molecules for targeting uchl5 |
| WO2020069105A1 (en) * | 2018-09-27 | 2020-04-02 | Dana-Farber Cancer Institute, Inc. | Degraders of wee1 kinase |
| AU2020224327B2 (en) * | 2019-02-21 | 2022-09-29 | Entact Bio Limited | Survival-targeting chimeric ( SURTAC) molecules |
| EP4090371A4 (en) * | 2020-01-14 | 2024-04-03 | The Trustees of Columbia University in the City of New York | COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY RE-ROUTING ENDOGENOUS DEUBIQUITINASES |
-
2022
- 2022-04-29 CA CA3216614A patent/CA3216614A1/en active Pending
- 2022-04-29 AU AU2022265718A patent/AU2022265718A1/en active Pending
- 2022-04-29 KR KR1020237040245A patent/KR20240004584A/ko active Pending
- 2022-04-29 IL IL307863A patent/IL307863A/en unknown
- 2022-04-29 BR BR112023022315A patent/BR112023022315A2/pt unknown
- 2022-04-29 US US18/288,550 patent/US20240252655A1/en active Pending
- 2022-04-29 WO PCT/US2022/027120 patent/WO2022232634A1/en not_active Ceased
- 2022-04-29 JP JP2023566513A patent/JP2024515828A/ja active Pending
- 2022-04-29 EP EP22724358.1A patent/EP4329815A1/en active Pending
- 2022-04-29 CN CN202280032073.1A patent/CN120225225A/zh active Pending
- 2022-04-29 MX MX2023012852A patent/MX2023012852A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4329815A1 (en) | 2024-03-06 |
| CA3216614A1 (en) | 2022-11-03 |
| CN120225225A (zh) | 2025-06-27 |
| MX2023012852A (es) | 2024-01-15 |
| US20240252655A1 (en) | 2024-08-01 |
| WO2022232634A1 (en) | 2022-11-03 |
| JP2024515828A (ja) | 2024-04-10 |
| BR112023022315A2 (pt) | 2024-02-20 |
| IL307863A (en) | 2023-12-01 |
| KR20240004584A (ko) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022232634A1 (en) | Deubiquitinase-targeting chimeras and related methods | |
| JP7005582B2 (ja) | ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物 | |
| RU2687060C2 (ru) | Фармацевтические соединения | |
| CN114057771B (zh) | 大环化合物及其制备方法和应用 | |
| EP3196197A1 (en) | Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor | |
| CN108601781A (zh) | 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用 | |
| EP3398950A1 (en) | Novel kinase inhibitor against wild-type egfr and mutated egfr | |
| EP2970249A2 (en) | Coumarin derivatives and methods of use in treating hyperproliferative diseases | |
| EA015103B1 (ru) | Производные n-фенил-2-пиримидинамина и способ их получения | |
| CN119371414A (zh) | 一类nsd蛋白降解剂及其用途 | |
| CN101151259B (zh) | 可用于抑制chk1的杂芳基脲衍生物 | |
| KR102678263B1 (ko) | 디히드로오로테이트 옥시게나제 억제제로서의 삼치환 벤조트리아졸 유도체의 사용 방법 | |
| JP2023554391A (ja) | キナーゼ阻害剤およびそれらの使用 | |
| EP3932915A1 (en) | Acryloyl-containing nuclear transport regulator and uses thereof | |
| CN107056789B (zh) | 具有取代吡嗪并咪唑类衍生物,其制备及其在医药上的应用 | |
| KR102717168B1 (ko) | 표적 단백질의 분해를 유도하기 위한 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 표적 단백질 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| US10590101B2 (en) | Benzo-N-hydroxy amide compounds having antitumor activity | |
| WO2024097355A1 (en) | Deubiquitinase-targeting chimeras and related methods | |
| US20250066353A1 (en) | Vanin-1 inhibitors | |
| Calder et al. | The Design, Synthesis, and Evaluation of Hypoxia-Activated Prodrugs of the KDAC Inhibitor Panobinostat | |
| EP4631931A1 (en) | Hdac inhibitor and use thereof | |
| HK40065003A (en) | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors | |
| EP4653442A1 (en) | Polycyclic compound for treating neurological diseases and tumors | |
| RU2801302C2 (ru) | Производные циклического иминопиримидина в качестве ингибиторов киназ | |
| EP4671245A1 (en) | HETEROAROMATIC CYCLIC COMPOUND SERVING AS A CDK7 KINASE INHIBITOR, ITS PREPARATION AND USE |